Key points are not available for this paper at this time.
The number of new genome-targeted cancer drugs has increased, offering the possibility of personalized therapy, often at a very high cost.
Tibau et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: